US Trial Finds AstraZeneca COVID-19 Vaccine 79 Percent Effective, No Blood Clot Risk

In this file photo taken on March 12, 2021 shows empty vials of the AstraZeneca Covid-19 vaccine at a vaccination center at the UBO (Universite Bretagne Occidentale) in Brest, western France.
The Netherlands suspends the use of AstraZeneca vaccine on March 14, 2021. Fred TANNEAU / AFP

AstraZeneca’s Covid-19 vaccine is 79 percent effective at preventing the disease and does not increase the risk of blood clots, the biotech firm said Monday, following its US phase III efficiency trials.

The shot was also 80 percent effective for the over 65s, it said. Several countries had advised against administering the jab to older people due to a lack of data among elderly participants in previous trials.

More to follow . . . 

READ  COVID-19: Africa’s Death Toll Surpasses 100,000


Please enter your comment!
Please enter your name here